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Abstract
The formation of new blood vessels from pre-existing ones is required for the growth of solid tumors and for metastasis. Inter-
action of tumor-secreted vascular endothelial growth factor (VEGF) with its receptor(s) on endothelial cells triggers endothe-
lial cell proliferation and migration, which facilitate tumor angiogenesis. Butyric acid (BuA), a fermentation product of dietary
fibers in the colon, is shown to alter gene expression and is postulated to be anticarcinogenic. The results presented in this
paper indicate that BuA can be antiangiogenic in vivo by inhibiting angiogenesis in chorioallantoic membrane assay. BuA was
not cytotoxic to endothelial cells but was a potent antiproliferative agent besides being proapoptotic to endothelial cells as verified
by FACS analysis. Conditioned media from BuA-treated Ehrlich ascites tumor cells showed a 30% decrease in VEGF concen-
tration when compared with untreated cells. The decrease in VEGF mRNA and its receptor, KDR mRNA levels in EAT and
endothelial cells respectively, suggests that the VEGF-KDR system of angiogenesis is the molecular target for the antiangiogenic
action of BuA. (Mol Cell Biochem 243: 107–112, 2003)
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Introduction
Tumor cells require large amounts of oxygen and nutrients
and need to recruit new blood vessels by angiogenesis to grow
beyond a critical size and for metastasis. The pivotal role of
VEGF and its receptors in tumor angiogenesis has been well
established. Production of VEGF in abundance by many tumor
cell lines and tumors and upregulation of VEGF receptor
expression in endothelial cells of tumor blood vessels reflect
on the involvement of VEGF in tumor neoangiogenesis [1–3].
Neutralization of VEGF or its receptors either by antibodies
or by use of dominant-negative mutants or soluble receptors,
profoundly decreased tumor growth in mice [4, 5]. The ex-
pression of VEGF is regulated by a plethora of external fac-
tors. VEGF production is potentiated by factors like FGF-4,
PDGF, TNF-α, TGF-β, KGF, IGF-1, IL-1β and IL-6 [6]. Other
cytokines such as IL-10 and IL-13 have been reported to
inhibit the release of VEGF [7]. Wild-type tumor suppressor
proteins, vHL, p53 and p73 have been shown to inhibit VEGF
gene expression [8–11]. Among synthetic, small molecular
weight inhibitors, fumagillin was identified as an angiogen-
esis inhibitor, since it inhibits endothelial cell proliferation
in vitro, angiogenesis in the chorioallantoic membrane (CAM)
assay and tumor growth and angiogenesis in the mouse [12].
Tyrosine kinase inhibitors, SU1498 and PTK787, selective
for VEGF receptor-2 (VEGFR-2/Flk-1/KDR) kinase, show
antiangiogenic effect in the CAM assay and bring about re-
gression of tumor growth [13]. Thrombospondin 1 (TSP1),
angiostatin and transforming growth factor-β (TGF-β) in-
hibit endothelial cell proliferation, migration and induce en-
dothelial cell apoptosis to bring about their antiangiogenic
effect [14–16].
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Dietary fibers (DF) have been shown to have beneficial
effects against a variety of diseases, such as colon cancer,
diabetes, coronary heart diseases, rheumatoid arthritis etc.
[17]. The DF are fermented by the microflora present in the
colon to short chain fatty acid (SCFA) such as acetate, pro-
pionate and butyrate. The SCFAs enter circulation and modu-
late activities of many key regulatory enzymes. Butyric acid
(BuA) has been implicated in the modulation of gene expres-
sion and induction of apoptosis [18, 19]. BuA is known to
induce apoptosis in a variety of tissue types including can-
cer cells [20, 21]. BuA has been postulated to bring about its
anticarcinogenic action in different ways like induction of
apoptosis, induction of cell differentiation, inhibition of his-
tone deacetylase leading to altered gene expression and re-
pression of specific cell death genes [22].
In this paper, we describe the molecular targets for the
antiangiogenic effect of BuA. BuA inhibits the expression of
angiogenic ligand and receptor genes and has an antipro-
liferative and proapoptotic effect on endothelial cells and can
thus act as a potent antiangiogenic compound.
Materials and methods
Materials
Fertilized eggs were purchased from the Government poultry
farm, Mysore, India. EAT cells were obtained from American
type cell culture, Rockville, USA. VEGF-ELISA kit was pur-
chased from R & D Systems, Germany. Endothelial growth
medium (EGM), endothelial basal medium (EBM) and fungi-
zone were obtained from Clonetech, NCTC-135, FCS, Peni-
cillin and streptomycin were purchased from Gibco, Germany.
RNeasy kit & QIAshredder were procured from Qiagen, Hil-
den, Germany. Quickhyb, RNase and BuA were procured from
Sigma-Aldrich, St. Louis, USA. All other reagents were of
analytical grade. EZ4U kit for cytotoxicity assay was obtained
from Biomedica, Austria. T7-Quickprime kit, Kodak X-Omat
X-ray film, Nick-column and α-32P labeled CTP were procured
from Amersham Pharmacia Biotech, Germany. The cDNA was
retrieved from the backbone vector using EcoR1/BamH1 for
human VEGF
165
 and Bgl II for human KDR.
Methods
Chorioallantoic membrane (CAM) assay
The fertilized eggs were incubated for 5 days at 37°C in a
humidified atmosphere. A window was made under aseptic
conditions on the eggshell to check for proper development
of the embryo. The window was resealed and the embryo was
allowed to develop further. On the 11th day, either saline or
BuA (1 mM) was air dried on a glass cover slip. The window
was reopened and the cover slip was inverted over the CAM.
The window was closed again and the eggs were incubated
for another 2 days. The window was opened on the 13th day
and inspected for changes in the microvessel density in the
area under the cover slip and photographed.
In vitro butyric acid treatment
EAT cells were grown in NCTC-135 medium with 10% FCS
and penicillin/streptomycin (1 mg/ml). HUVECs were grown
in gelatin coated flasks using EGM with 5% FCS and peni-
cillin/streptomycin (1 mg/ml). After the cells were 80% con-
fluent, they were treated with various concentrations of BuA
(0–20 mM) for various time periods (0–24 h). Then, the cells
were trypsinized and collected before being used for further
experiments.
Cytotoxicity assay
Cytotoxicity assay for BuA was done using the EZ4U kit as
per the manufacturer’s instructions. In brief, 50,000 HUVECs
were plated in 96-well plates and grown overnight. After
addition of varying concentrations of BuA (0–20 mM), 20
µl of substrate (Tetrazolium compound) was added to each
well and incubated for 4 h at 37°C. Absorption at 450 nm was
measured.
Assay for proliferation of HUVECs
Cells (HUVECs) were plated at a concentration of 100,000
cells/well in 6-well cluster plates. Twenty-four h after plat-
ing, cells were treated with varying concentrations of BuA
(0–10 mM) and further cultured for 2 days at 37°C and 5%
CO
2
. Thereafter, cells were trypsinized and counted using a
Coulter Counter.
Fluorescence activated cell sorter (FACS) analysis
HUVECs were grown to 80% confluence and treated with 10
mM BuA for various time intervals (0–24 h). The cells were
harvested by trypsinization and fixed in ice-cold methanol
overnight at 4°C. The cells were centrifuged, rehydrated us-
ing PBS, washed once and transferred to FACS tubes. The cells
were then treated with 5 µl of RNase (10 mg/ml) and 20 µl of
propidium iodide (1 mg/ml) and incubated in the dark at room
temperature for at least 30 min, before processing for FACS
analysis using a FACSCalibur machine. 20,000 events were
counted. Data were analyzed using Win MDI 2.8 software.
Vascular endothelial growth factor-enzyme linked
immunosorbent assay
VEGF-ELISA was performed using a kit method as per the
manufacturer’s instructions. In brief, 50 µl of each of assay
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diluent and samples were added to a 96-well microplate pre-
coated with mouse VEGF polyclonal antibody. Recombin-
ant mouse VEGF was used to set up the standard curve. After
2 h of incubation, the wells were washed before adding 100
µl of polycolonal antimouse VEGF conjugated to horserad-
ish peroxidase. After incubation for 2 h at room temperature
and washing, 100 µl of substrate solution was added and in-
cubated for 30 min at room temperature. The reaction was
stopped and the O.D. at 450 nm (correction wavelength set
at 510 nm) was measured in a Multiskan Ascent v22. A stand-
ard graph was generated using the Multiskan Ascent software
with four-parameter logistic fit.
Northern blot analysis
Total RNA was extracted from confluent HUVECs and EAT
cells using an RNeasy kit according to the instructions from
the manufacturer. Total RNA (15 µg) was separated by 0.8%
agarose-formaldehyde gel electrophoresis and blotted onto
nylon membrane which was baked and hybridized with α(32P)-
dCTP-labelled VEGF
165
 or KDR cDNA. The hybridized blot
was processed and subjected to autoradiography at –70°C.
All blots after autoradiography were stripped and reprobed
for expression of GAPDH as an internal control using labeled
GAPDH cDNA.
Results
Angioinhibitory effect of BuA
In vivo angioinhibitory effect of BuA was clearly evident
from results obtained in chorioallantoic membrane (CAM)
assay. Results shown in Fig. 1 indicate that when compared
to the extensive angiogenesis seen in normal CAM, angio-
genesis in the CAM at the site of application of BuA was
reduced significantly.
Kinetics of gene expression of VEGF and KDR in response
to BuA treatment
The angioinhibitory effect of BuA could be attributed to its
effect on either angiogenic ligand/receptor gene expression
and/or to its effect on endothelial cell proliferation and ap-
optosis. The results in Fig. 2 show that over a period of 24 h
in BuA-treated EAT cells, the VEGF mRNA levels decrease
considerably. KDR mRNA levels in BuA-treated HUVECs
were also significantly reduced in a time dependent manner.
The decrease in VEGF gene expression was corroborated by
the reduction in the amount of VEGF protein as estimated by
VEGF-ELISA in the conditioned media of cells treated with
BuA.
BuA inhibits VEGF production in EAT cells
Figure 3 compares the amount of VEGF in conditioned media
at different time intervals over a period of 24 h for untreated
and BuA (10 mM)-treated EAT cells. The results indicate that
BuA has a time-dependent inhibitory effect on the release of
VEGF in EAT cells under in vitro conditions. When compared
to control, approximately 30% inhibition is seen in the amount
of protein expressed (at 8 h and above) in BuA-treated cells.
Antiproliferative effect of BuA
The proliferation of endothelial cells induced by an ang-
iogenic ligand determines the extent of angiogenesis. The
possibility of BuA influencing the growth of endothelial cells
therefore reflects on its antiangiogenic effect. The results in Fig.
4B indicate that BuA inhibited the proliferation of HUVECs
in vitro in a dose-dependent manner. To rule out the possibil-
ity that the antiproliferative effect of BuA on HUVECs was
not due to cytotoxicity of BuA, a cytotoxicity test was per-
formed. BuA did not show any cytotoxicity towards HUVECs
at the concentration of 0–10 mM in vitro (Fig. 4A).
BuA induces apoptosis of HUVECs
The results on inhibition of growth of HUVECs in vitro clearly
indicate the involvement of the process of apoptosis. To verify
this, HUVECs were subjected to FACS analysis, where sig-
nificant increase of events in the sub-G1 phase in BuA-treated
cells confirmed induction of apoptosis in HUVECs by BuA
(Fig. 5).
Fig. 1. Angioinhibitory effect of BuA. Either saline or BuA (1 mM) was
dried on cover slips and applied onto the CAM of the developing chick
embryo through a cut window. The CAM was observed for inhibition of
neovascularization. The data shown represents the result of an experiment
which was done using a minimum of six eggs in each group.
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Discussion
In the present study, we have focused our attention on delin-
eating the pleiotropic effects of BuA, the fermentation prod-
uct of dietary fiber in the colon, as a potent antiangiogenic
compound.
Our results show that there is inhibition of neovasculariza-
tion by BuA in CAM. CAM assay is an assay commonly used
to identify antiangiogenic compounds. Since there is inhibi-
tion of neovascularization by BuA, it supports our view that
BuA may repress the expression of VEGF-like factors or
inhibit the secretion of such factors, thereby inhibiting the
formation of new blood vessels. This hypothesis is further
confirmed by our results on Northern blot analysis and VEGF-
ELISA where BuA was able to inhibit VEGF gene expression
effectively in a time dependent manner, at a concentration that
it is present in the body. Recent studies suggest that endothe-
lial cell apoptosis is necessary for the repair of damaged blood
vessels and for sprouting and branching of capillaries dur-
ing angiogenesis [23, 24]. Traditionally, regression of neo-
vascular responses has been associated with inhibition of
endothelial cell proliferation, migration and adhesion. Re-
cently, the role of endothelial cell survival and death signals
Fig. 2. Effect of BuA on expression of VEGF mRNA in EAT cells and KDR mRNA in HUVECs. Total RNA from EAT cells or HUVECs was isolated
after treatment with BuA for varying time periods (Lane 1: Control, Lanes 2–6: 2–24 h) and Northern blot analysis was performed using VEGF165 and KDR
cDNA labeled probes. GAPDH was used as an internal control. The representative Northern blots and the graph depicting quantitation of VEGF and KDR
mRNA is shown. The experiment was performed 3 times.
Fig. 3. Expression of VEGF protein by EAT cells in response to BuA. Con-
ditioned media from EAT cells treated with and without BuA for various
time periods (0–24 h) was subjected to VEGF-ELISA. Values are normal-
ized to cell number and are expressed as mean ± S.E.M. of experiment done
in triplicate.
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Fig. 4. Antiproliferative effect of BuA. (A) 50,000 cells were plated in 96-well plates and incubated overnight. Various concentrations of BuA were added
and incubated for 5 h before the cytotoxicity was assayed. Results are expressed as mean O.D. ± S.E.M. (B) 100,000 cells were plated in 6-well plates and
incubated overnight. Cells were treated with varying concentrations of BuA and after 2 days were counted in a Coulter counter. Values are mean of tripli-
cates ± S.E.M.
Fig. 5. Analysis of induction of apoptosis in HUVECs by BuA. HUVECs were grown to approximately 80% confluence and treated with or without BuA
(10 mM) for 24 h. Cells were trypsinized and processed for FACS analysis.
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in sustaining and disrupting neovascularization have been
recognized. It is now well established that key regulators of
angiogenesis function, at least in part, by modulating the
survival of endothelial cells during the process of vessel re-
pair and angiogenesis. Many proangiogenic factors act as
endothelial cell survival factors while antiangiogenic factors
induce endothelial cell apoptosis [25]. BuA was found to be
an antiangiogenic compound [19]. The efficacy of BuA as an
inducer of endothelial cell apoptosis was therefore verified.
The results of FACS analysis show that the number of events
in the sub-G1 phase, which are indicative of apoptotic bod-
ies and condensed nuclei, was increased in BuA treated cells.
Apart from being a direct inducer of apoptosis of endothe-
lial cells, BuA may act as a apoptotic agent in vivo for en-
dothelial cells by inhibiting the expression of VEGF, which
is a survival factor for these cells and this could be one of
the mechanisms by which it induces its in vivo antiangiogenic
effect. Inhibition of angiogenic receptor (KDR) gene expres-
sion by BuA indicates that BuA acts at multiple sites to effec-
tively inhibit angiogenesis. Since BuA has a high metabolic
turnover rate in vivo, structural analogues of BuA with in-
creased stability would be useful as in vivo antiangiogenic
compounds.
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